This finding is in contrast with previous observations indicating that oral contraceptive users were characterized by higher incidence of hyperprolactinemia than control subjects, and that the increase in prolactin levels was noted in 12–30% of patients receiving higher estrogen-containing oral contraceptives [26]. The gene discussed is PRL; the disease is hyperprolactinemia.